SUNNYVALE, Calif., Sept. 1, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the medical care
team at University Hospital Città della Salute e della
Scienza, in Turin, Italy have
treated the first cancer patients in the Europe, India, Middle
East and Africa (EIMEA)
region using the Radixact® System with
Synchrony® Automatic, Real-time Motion Synchronization
Technology[1]. The Accuray-exclusive Synchrony technology leverages
the Radixact System's fully integrated, real-time imaging to
automatically adapt the treatment delivery to cancer targets as
they move during treatment. The result is truly personalized care —
the treatment is adapted to the individual and unique movements of
each patient or the treatment target throughout the entire
radiation delivery session.
The installation of the Radixact System with Synchrony
technology is an important milestone for residents of Turin and the Piedmont region of Italy, who will now have access to one of the
world's most advanced radiation therapy systems within their
community. The first patient treated was an 85-year-old man with
early stage lung cancer, a tumor that continuously moves with
respiration. Because he suffered from severe impairments in lung
function, surgery and conventional radiation therapy options were
deemed too risky. The Radixact System with Synchrony provided the
academic team with the ability to precisely and accurately deliver
the optimal radiation dose to the location of the tumor as it moved
with respiration, enabling them to destroy the cancer cells while
minimizing the risk of damage to the patient's vital lung and
surrounding healthy tissues.
The Radixact platform further improved therapeutic options
offered at the University Hospital Città della Salute e della
Scienza, whose academic team has been deeply involved in clinical
and scientific research in thoracic oncology, and has had an active
stereotactic body radiation therapy (SBRT) program since 2003. The
addition of Synchrony to the Radixact System made it easier for the
team to administer SBRT to the patient; high doses of radiation
were delivered in just five treatment sessions, limiting the
volumes of normal lung exposed to irradiation.
Click here to see how the Radixact System with Synchrony
treats lung tumors.
"The University Hospital team is dedicated to expanding access
to exceptional cancer care within our community. Our first patient
treatment demonstrates the value the innovative Radixact and
Synchrony technologies can provide to our patients, some of whom
would have been without curative options," said Umberto Ricardi, Professor of Radiation Oncology
at the University of Turin, Chair
of the Department of Oncology of the hospital, and immediate past
president of the European Society for Radiotherapy and Oncology
(ESTRO). "The Radixact System with Synchrony will enable our team
to effectively and efficiently treat more fragile lung cancer
patients, offering a compelling therapeutic option even for these
very tricky cases."
"We congratulate Professor Ricardi and the team on treating the
first cancer patients in EIMEA using the Radixact System with
Synchrony. We are proud to have the opportunity to partner with the
team to advance cancer care in Italy," said Joshua H.
Levine, president and chief executive officer of Accuray.
"Accuray introduced Synchrony for the Radixact System to provide
clinicians with an efficient, easy-to-use, and automated method of
tracking and treating tumors as they move. We believe that use of
this innovative capability will improve dose accuracy, treatment
times, and patient comfort, when compared to conventional methods,
such as gating, and expand access to high-precision,
ultra-hypofractionated radiation therapy treatments to more
patients."
Working with distributor partners has enabled Accuray to extend
its business into multiple areas of the world. Tecnologie Avanzate
S.r.l., as the exclusive distributor for the Accuray
TomoTherapy® platform in Italy, including the next-generation
Radixact® System, worked with the University Hospital
medical care and administrative team as they evaluated radiation
therapy systems and selected the Radixact System and
Synchrony® technology.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiation therapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products; the company's ability to develop
new products or improve existing products to meet customers' needs;
the company's ability to anticipate or keep pace with changes in
the marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's quarterly report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
May 8, 2020, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
[1] "Synchrony® Automatic, Real-time Motion
Synchronization Technology" is synonymous with the development
name: "Motion Tracking and Compensation Feature for the
Radixact® Treatment Delivery System"
View original content to download
multimedia:http://www.prnewswire.com/news-releases/university-hospital-citta-della-salute-e-della-scienza-turin-italy-is-first-in-eimea-to-treat-cancer-patients-using-the-accuray-radixact-system-with-synchrony-technology-301121521.html
SOURCE Accuray Incorporated